Exciting Business Update from SIGA Technologies
SIGA Technologies, Inc. (SIGA), a prominent player in the pharmaceutical industry, is gearing up for a business update call set for March 11, 2025. During this session, the leadership team will share vital information about the company's performance and strategic plans moving forward.
Details of the Upcoming Call
Scheduled to commence at 4:30 P.M. ET, the call will feature insights from Diem Nguyen, the Chief Executive Officer, and Daniel Luckshire, the Chief Financial Officer. This call presents a valuable opportunity for investors and stakeholders to gain a deeper understanding of SIGA's direction and future prospects.
Accessing the Webcast
For those interested in participating, a live webcast will be available on the company’s website. Participants are encouraged to log in a few minutes before the call starts to ensure a seamless experience. This kind of proactive engagement is essential for stakeholders looking to stay up-to-date with SIGA's developments.
Call Access Information
To join the call, domestic callers can dial 1-800-717-1738, while international participants can reach out at 1-646-307-1865. This easy access reflects SIGA's commitment to maintaining transparent communication with its audience.
Post-Call Replay and Archive
If you miss the live event, don't worry! A replay of the call will be accessible for two weeks after the event. This convenience allows everyone to stay informed, irrespective of their schedules. Simply dial the provided numbers with the appropriate Conference ID to catch up on what you may have missed.
About SIGA Technologies
SIGA Technologies is known for its commitment to public health and safety. The company focuses on developing innovative antiviral medications to combat various infectious diseases, particularly those involving orthopoxviruses. One of their flagship products, TPOXX, is gaining recognition in the medical field for its effectiveness in treating smallpox and other related diseases.
As part of its mission, SIGA collaborates with numerous health organizations and government agencies to fortify global health infrastructures. By producing essential medical countermeasures, the company aims to minimize the impact of biological threats on society.
Contact Information for Inquiries
For those seeking further information, SIGA Technologies has dedicated contacts available for both media and investor inquiries. Suzanne Harnett is available for direct contact at sharnett@siga.com, while Jennifer Drew-Bear and Holly Stevens provide additional resources for investors and media respectively.
Frequently Asked Questions
What is the purpose of the upcoming SIGA Technologies call?
The call aims to provide a business update and discuss the company's financial health and strategy.
How can I access the live webcast?
The live webcast will be accessible through SIGA's official website, specifically in the Investor Relations section.
Who will be speaking during the call?
The call features Diem Nguyen, CEO, and Daniel Luckshire, CFO, sharing insights about the company's performance.
What are the options for accessing the call?
Participants can join the call via phone for both domestic and international lines, ensuring wide accessibility.
What is TPOXX and why is it significant?
TPOXX is SIGA’s antiviral drug, approved for treating smallpox and recognized for its importance in managing serious infectious diseases.